Cargando…
The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial
BACKGROUND: The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and the more aggressive subtype, nonalcoholic steatohepatitis (NASH), is a global public health concern. Left untreated, NAFLD/NASH can lead to cirrhosis, liver failure, and death. The current standard for diagnosing and s...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652684/ https://www.ncbi.nlm.nih.gov/pubmed/33104014 http://dx.doi.org/10.2196/19189 |
_version_ | 1783607742323228672 |
---|---|
author | Tonev, Dimitar Shumbayawonda, Elizabeth Tetlow, Louise Ann Herdman, Laura French, Marika Rymell, Soubera Thomaides-Brears, Helena Caseiro-Alves, Filipe Castelo-Branco, Miguel Ferreira, Carlos Coenraad, Minneke Lamb, Hildo Beer, Meinrad Kelly, Matt Banerjee, Rajarshi Dollinger, Matthias |
author_facet | Tonev, Dimitar Shumbayawonda, Elizabeth Tetlow, Louise Ann Herdman, Laura French, Marika Rymell, Soubera Thomaides-Brears, Helena Caseiro-Alves, Filipe Castelo-Branco, Miguel Ferreira, Carlos Coenraad, Minneke Lamb, Hildo Beer, Meinrad Kelly, Matt Banerjee, Rajarshi Dollinger, Matthias |
author_sort | Tonev, Dimitar |
collection | PubMed |
description | BACKGROUND: The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and the more aggressive subtype, nonalcoholic steatohepatitis (NASH), is a global public health concern. Left untreated, NAFLD/NASH can lead to cirrhosis, liver failure, and death. The current standard for diagnosing and staging liver disease is a liver biopsy, which is costly, invasive, and carries risk for the patient. Therefore, there is a growing need for a reliable, feasible, and cost-effective, noninvasive diagnostic tool for these conditions. LiverMultiScan is one such promising tool that uses multi-parametric magnetic resonance imaging (mpMRI) to characterize liver tissue and to aid in the diagnosis and monitoring of liver diseases of various etiologies. OBJECTIVE: The primary objective of this trial (RADIcAL1) is to evaluate the cost-effectiveness of the introduction of LiverMultiScan as a standardized diagnostic test for liver disease in comparison to standard care for NAFLD, in different EU territories. METHODS: RADIcAL1 is a multi-center randomized control trial with 2 arms conducted in 4 European territories (13 sites, from across Germany, Netherlands, Portugal, and the United Kingdom). In total, 1072 adult patients with suspected fatty liver disease will be randomized to be treated according to the result of the mpMRI in the intervention arm, so that further diagnostic evaluation is recommended only when values for metrics of liver fat or fibro-inflammation are elevated. Patients in the control arm will be treated as per center guidelines for standard of care. The primary outcome for this trial is to compare the difference in the proportion of patients with suspected NAFLD incurring liver-related hospital consultations or liver biopsies between the study arms, from the date of randomization to the end of the study follow-up. Secondary outcomes include patient feedback from a patient satisfaction questionnaire, at baseline and all follow-up visits to the end of the study, and time, from randomization to diagnosis by the physician, as recorded at the final follow-up visit. RESULTS: This trial is currently open for recruitment. The anticipated completion date for the study is December 2020. CONCLUSIONS: This randomized controlled trial will provide the evidence to accelerate decision making regarding the inclusion of mpMRI-based tools in existing NAFLD/NASH clinical care. RADIcAL1 is among the first and largest European health economic studies of imaging technologies for fatty liver disease. Strengths of the trial include a high-quality research design and an in-depth assessment of the implementation of the cost-effectiveness of the mpMRI diagnostic. If effective, the trial may highlight the health economic burden on tertiary-referral hepatology clinics imposed by unnecessary consultations and invasive diagnostic investigations, and demonstrate that including LiverMultiScan as a NAFLD diagnostic test may be cost-effective compared to liver-related hospital consultations or liver biopsies. TRIAL REGISTRATION: ClinicalTrials.gov NCT03289897 https://clinicaltrials.gov/ct2/show/NCT03289897 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/19189 |
format | Online Article Text |
id | pubmed-7652684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76526842020-11-13 The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial Tonev, Dimitar Shumbayawonda, Elizabeth Tetlow, Louise Ann Herdman, Laura French, Marika Rymell, Soubera Thomaides-Brears, Helena Caseiro-Alves, Filipe Castelo-Branco, Miguel Ferreira, Carlos Coenraad, Minneke Lamb, Hildo Beer, Meinrad Kelly, Matt Banerjee, Rajarshi Dollinger, Matthias JMIR Res Protoc Protocol BACKGROUND: The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and the more aggressive subtype, nonalcoholic steatohepatitis (NASH), is a global public health concern. Left untreated, NAFLD/NASH can lead to cirrhosis, liver failure, and death. The current standard for diagnosing and staging liver disease is a liver biopsy, which is costly, invasive, and carries risk for the patient. Therefore, there is a growing need for a reliable, feasible, and cost-effective, noninvasive diagnostic tool for these conditions. LiverMultiScan is one such promising tool that uses multi-parametric magnetic resonance imaging (mpMRI) to characterize liver tissue and to aid in the diagnosis and monitoring of liver diseases of various etiologies. OBJECTIVE: The primary objective of this trial (RADIcAL1) is to evaluate the cost-effectiveness of the introduction of LiverMultiScan as a standardized diagnostic test for liver disease in comparison to standard care for NAFLD, in different EU territories. METHODS: RADIcAL1 is a multi-center randomized control trial with 2 arms conducted in 4 European territories (13 sites, from across Germany, Netherlands, Portugal, and the United Kingdom). In total, 1072 adult patients with suspected fatty liver disease will be randomized to be treated according to the result of the mpMRI in the intervention arm, so that further diagnostic evaluation is recommended only when values for metrics of liver fat or fibro-inflammation are elevated. Patients in the control arm will be treated as per center guidelines for standard of care. The primary outcome for this trial is to compare the difference in the proportion of patients with suspected NAFLD incurring liver-related hospital consultations or liver biopsies between the study arms, from the date of randomization to the end of the study follow-up. Secondary outcomes include patient feedback from a patient satisfaction questionnaire, at baseline and all follow-up visits to the end of the study, and time, from randomization to diagnosis by the physician, as recorded at the final follow-up visit. RESULTS: This trial is currently open for recruitment. The anticipated completion date for the study is December 2020. CONCLUSIONS: This randomized controlled trial will provide the evidence to accelerate decision making regarding the inclusion of mpMRI-based tools in existing NAFLD/NASH clinical care. RADIcAL1 is among the first and largest European health economic studies of imaging technologies for fatty liver disease. Strengths of the trial include a high-quality research design and an in-depth assessment of the implementation of the cost-effectiveness of the mpMRI diagnostic. If effective, the trial may highlight the health economic burden on tertiary-referral hepatology clinics imposed by unnecessary consultations and invasive diagnostic investigations, and demonstrate that including LiverMultiScan as a NAFLD diagnostic test may be cost-effective compared to liver-related hospital consultations or liver biopsies. TRIAL REGISTRATION: ClinicalTrials.gov NCT03289897 https://clinicaltrials.gov/ct2/show/NCT03289897 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/19189 JMIR Publications 2020-10-26 /pmc/articles/PMC7652684/ /pubmed/33104014 http://dx.doi.org/10.2196/19189 Text en ©Dimitar Tonev, Elizabeth Shumbayawonda, Louise Ann Tetlow, Laura Herdman, Marika French, Soubera Rymell, Helena Thomaides-Brears, Filipe Caseiro-Alves, Miguel Castelo-Branco, Carlos Ferreira, Minneke Coenraad, Hildo Lamb, Meinrad Beer, Matt Kelly, Rajarshi Banerjee, Matthias Dollinger, RADIcAL1. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 26.10.2020. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included. |
spellingShingle | Protocol Tonev, Dimitar Shumbayawonda, Elizabeth Tetlow, Louise Ann Herdman, Laura French, Marika Rymell, Soubera Thomaides-Brears, Helena Caseiro-Alves, Filipe Castelo-Branco, Miguel Ferreira, Carlos Coenraad, Minneke Lamb, Hildo Beer, Meinrad Kelly, Matt Banerjee, Rajarshi Dollinger, Matthias The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title | The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title_full | The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title_fullStr | The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title_full_unstemmed | The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title_short | The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial |
title_sort | effect of multi-parametric magnetic resonance imaging in standard of care for nonalcoholic fatty liver disease: protocol for a randomized control trial |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652684/ https://www.ncbi.nlm.nih.gov/pubmed/33104014 http://dx.doi.org/10.2196/19189 |
work_keys_str_mv | AT tonevdimitar theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT shumbayawondaelizabeth theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT tetlowlouiseann theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT herdmanlaura theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT frenchmarika theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT rymellsoubera theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT thomaidesbrearshelena theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT caseiroalvesfilipe theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT castelobrancomiguel theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT ferreiracarlos theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT coenraadminneke theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT lambhildo theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT beermeinrad theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT kellymatt theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT banerjeerajarshi theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT dollingermatthias theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT theeffectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT tonevdimitar effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT shumbayawondaelizabeth effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT tetlowlouiseann effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT herdmanlaura effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT frenchmarika effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT rymellsoubera effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT thomaidesbrearshelena effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT caseiroalvesfilipe effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT castelobrancomiguel effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT ferreiracarlos effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT coenraadminneke effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT lambhildo effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT beermeinrad effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT kellymatt effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT banerjeerajarshi effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT dollingermatthias effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial AT effectofmultiparametricmagneticresonanceimaginginstandardofcarefornonalcoholicfattyliverdiseaseprotocolforarandomizedcontroltrial |